Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options

Oncogenesis

Volumn 4, Issue 3, 2015, Pages

  Loupe, J M ^a,c   Miller, P J ^a,d   Ruffin, D R ^b   Stark, M W ^b   Hollenbach, A D ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; SERINE; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3;

ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MUSCLE DEVELOPMENT; ONCOGENE; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RHABDOMYOSARCOMA; TUMOR CELL; VELOCITY; WOUND HEALING;

EID: 84989960766     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2015.2     Document Type: Article

References (47)

1. Ognjanovic S, Linabery AM, Charbonneau B, Ross JA. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer 2009; 115: 4218-4226.
2. Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001; 20: 5736-5746.
3. Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res 1993; 53: 5108-5112.
4. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ 3rd, Emanuel BS et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993; 5: 230-235.
5. Hollenbach AD, Sublett JE, McPherson CJ, Grosveld G. The Pax3-FKHR oncoprotein is unresponsive to the Pax3-associated repressor hDaxx. Embo J 1999; 18: 3702-3711.
6. Miller PJ, Hollenbach AD. The oncogenic fusion protein Pax3-FKHR has a greater post-translational stability relative to Pax3 during early myogenesis. Biochim Biophys Acta 2007; 1770: 1450-1458.
7. Fredericks WJ, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG et al. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 1995; 15: 1522-1535.
8. Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001; 11: 289-297.
9. Epstein JA, Song B, Lakkis M, Wang C. Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor. Mol Cell Biol 1998; 18: 4118-4130.
10. Ginsberg JP, Davis RJ, Bennicelli JL, Nauta LE, Barr FG. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res 1998; 58: 3542-3546.
11. Linardic CM. PAX3-FOXO1 fusion gene in rhabdomyosarcoma. Cancer Lett 2008; 270: 10-18.
12. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the children's oncology group. J Clin Oncol 2002; 20: 2672-2679.
13. Force T, Kuida K, Namchuk M, Parang K, Kyriakis JM. Inhibitors of protein kinase signaling pathways: Emerging therapies for cardiovascular disease. Circulation 2004; 109: 1196-1205.
14. Fang B, Haura EB, Smalley KS, Eschrich SA, Koomen JM. Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling. Biochem Pharmacol 2010; 80: 739-747.
15. Dietz KN, Miller PJ, Hollenbach AD. Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation. Biochemistry 2009; 48: 11786-11795.
16. Dietz KN, Miller PJ, Iyengar AS, Loupe JM, Hollenbach AD. Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation. Int J Biochem Cell Biol 2011; 43: 936-945.
17. Miller PJ, Dietz KN, Hollenbach AD. Identification of serine 205 as a site of phosphorylation on Pax3 in proliferating but not differentiating primary myoblasts. Protein Sci 2008; 17: 1979-1986.
18. Amstutz R, Wachtel M, Troxler H, Kleinert P, Ebauer M, Haneke T et al. Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities. Cancer Res 2008; 68: 3767-3776.
19. Zeng FY, Dong H, Cui J, Liu L, Chen T. Glycogen synthase kinase 3 regulates PAX3- FKHR-mediated cell proliferation in human alveolar rhabdomyosarcoma cells. Biochem Biophys Res Commun 2010; 391: 1049-1055.
20. Jope RS. Lithium and GSK-3: One inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003; 24: 441-443.
21. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003; 278: 45937-45945.
22. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H et al. The selectivity of protein kinase inhibitors: A further update. Biochem J 2007; 408: 297-315.
23. Dionyssiou MG, Ehyai S, Avrutin E, Connor MK, McDermott JC. Glycogen synthase kinase 3beta represses MYOGENIN function in alveolar rhabdomyosarcoma. Cell Death Dis 2014; 5: E1094.
24. Chen EY, DeRan MT, Ignatius MS, Grandinetti KB, Clagg R, McCarthy KM et al. Glycogen synthase kinase 3 inhibitors induce the canonical WNT/beta-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma. Proc Natl Acad Sci USA 2014; 111: 5349-5354.
25. Thuault S, Hayashi S, Lagirand-Cantaloube J, Plutoni C, Comunale F, Delattre O et al. P-cadherin is a direct PAX3-FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness. Oncogene 2013; 32: 1876-1887.
26. Iyengar AS, Loupe JM, Miller PJ, Hollenbach AD. Identification of CK2 as the kinase that phosphorylates Pax3 at Ser209 in early myogenic differentiation. Biochem Biophys Res Commun 2012; 428: 24-30.
27. Iyengar AS, Miller PJ, Loupe JM, Hollenbach AD. Phosphorylation of PAX3 contributes to melanoma phenotypes by affecting proliferation, invasion, and transformation. Pigment Cell Melanoma Res 2014; 27: 846-848.
28. Noda T, Todani T, Watanabe Y, Uemura S, Urushihara N, Morotomi Y et al. Alveolar rhabdomyosarcoma of the lung in a child. J Pediatr Surg 1995; 30: 1607-1608.
29. Lokesh KN, Premalata CS, Aruna Kumari BS, Appaji L. Primary pulmonary rhabdomyosarcoma in children: Report of three cases with review of literature. Indian J Med Paediatr Oncol 2013; 34: 38-41.
30. Punyko JA, Mertens AC, Baker KS, Ness KK, Robison LL, Gurney JG. Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation. Cancer 2005; 103: 1475-1483.
31. Meza JL, Anderson J, Pappo AS, Meyer WH. Children's Oncology G. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: The Children's Oncology Group. J Clin Oncol 2006; 24: 3844-3851.
32. Subbiah V, Kurzrock R. Phase 1 clinical trials for sarcomas: The cutting edge. Curr Opin Oncol 2011; 23: 352-360.
33. Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group. Pediatr Blood Cancer 2014; 61: 452-456.
34. Casali PG. Histology- And non-histology-driven therapy for treatment of soft tissue sarcomas. Ann Oncol 2012; 23(Suppl 10): X167-x169.
35. Kikuchi K, Tsuchiya K, Otabe O, Gotoh T, Tamura S, Katsumi Y et al. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun 2008; 365: 568-574.
36. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39.
37. Parham DM. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod Pathol 2001; 14: 506-514.
38. Hazelton BJ, Houghton JA, Parham DM, Douglass EC, Torrance PM, Holt H et al. Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res 1987; 47: 4501-4507.
39. Hinson AR, Jones R, Crose LE, Belyea BC, Barr FG, Linardic CM. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: Utility and pitfalls. Front Oncol 2013; 3: 183.
40. Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 2009; 273: 194-200.
41. Dominguez JM, Fuertes A, Orozco L, del Monte-Millan M, Delgado E, Medina M. Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem 2012; 287: 893-904.
42. Novetsky AP, Thompson DM, Zighelboim I, Thaker PH, Powell MA, Mutch DG et al. Lithium chloride and inhibition of glycogen synthase kinase 3beta as a potential therapy for serous ovarian cancer. Int J Gynecol Cancer 2013; 23: 361-366.
43. Li H, Huang K, Liu X, Liu J, Lu X, Tao K et al. Lithium chloride suppresses colorectal cancer cell survival and proliferation through ROS/GSK-3beta/NF-kappaB signaling pathway. Oxid Med Cell Longev 2014; 2014: 241864.
44. Bilir A, Erguven M, Yazihan N, Aktas E, Oktem G, Sabanci A. Enhancement of vinorelbine-induced cytotoxicity and apoptosis by clomipramine and lithium chloride in human neuroblastoma cancer cell line SH-SY5Y. J Neuro-oncol 2010; 100: 385-395.
45. Sun A, Shanmugam I, Song J, Terranova PF, Thrasher JB, Li B. Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer. Prostate 2007; 67: 976-988.
46. Laker C, Meyer J, Schopen A, Friel J, Heberlein C, Ostertag W et al. Host cis-mediated extinction of a retrovirus permissive for expression in embryonal stem cells during differentiation. J Virol 1998; 72: 339-348.
47. Lam PY, Sublett JE, Hollenbach AD, Roussel MF. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. Mol Cell Biol 1999; 19: 594-601.